Brazil is a strategically important market with a population of over 210 million and a pharmaceutical market value of around A$24 billion per annum, with new patients registering daily for MGC Pharma products after the first week.
() has completed its first-ever shipments of the Mercury Pharma line, which includes high THC products, directly to patients in Brazil through a binding supply and distribution agreement with ONIX Empreendimentos e Participações.
The company has become the first globally to ship high THC formations directly to a patient’s door in Brazil, marking a first major operational achievement.
ONIX has launched the second generation of its CANTERAMED platform to help doctors better service their patients.
This platform has facilitated the doctor’s practice with its protocols to use MGC Pharma products and register treatment results.
CANTERAMED includes a telemedicine platform that connects patients with doctors trained to prescribe MGC Pharma products.
“Rapidly increasing demand”
Co-founder and MD Roby Zomer said: “This is an incredible achievement as no other company has shipped high THC formulations directly to patients in Brazil before.
“We have been working closely with our Brazilian partner ONIX and remain confident that Brazil will be a huge strategically and commercially important region for us going forward.
“Feedback to date from patients in Brazil has been extremely positive and we are seeing rapidly increasing demand for our Mercury Pharma products.”
The shipment of Mercury Pharma branded products directly to patients is in compliance with Brazil’s Compassionate Use Program, following the receipt of patients’ prescriptions provided by an ONIX referring doctor.
ONIX has more than 100 referring doctors in Brazil able to prescribe cannabinoid products under the Compassionate Use Program and is targeting to have more than 300 referring doctors by the end of calendar 2020 as well as more than 1,000 by mid-2021.